Minimal Residual Disease Detection in Acute Leukemia Patients by Flow Cytometric Assay of Cross-lineage Antigen Expression.
10.3343/kjlm.2010.30.6.533
- Author:
Young Uk CHO
1
;
Chan Jeoung PARK
;
Choong Hwan CHA
;
Hyun Sook CHI
;
Seongsoo JANG
;
Mi Jung KIM
;
Kyoo Hyung LEE
;
Je Hwan LEE
;
Jung Hee LEE
;
Jong Jin SEO
;
Ho Joon IM
Author Information
1. Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. cjpark@amc.seoul.kr
- Publication Type:Original Article ; English Abstract ; Research Support, Non-U.S. Gov't
- Keywords:
Minimal residual disease;
Acute leukemia;
Flow cytometric assay;
Cross-lineage antigen expression
- MeSH:
Acute Disease;
Adolescent;
Adult;
Aged;
Antigens/*metabolism;
Antigens, CD/metabolism;
Bone Marrow/metabolism;
Child;
Child, Preschool;
Disease-Free Survival;
Female;
*Flow Cytometry;
Humans;
Infant;
Leukemia, Myeloid, Acute/*diagnosis/mortality/therapy;
Male;
Middle Aged;
Neoplasm, Residual/diagnosis;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis/mortality/therapy;
Recurrence;
Survival Rate
- From:The Korean Journal of Laboratory Medicine
2010;30(6):533-539
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: It has been demonstrated that flow cytometric detection of minimal residual disease (MRD) has a prognostic significance in the treatment of patients with acute leukemia. We investigated the significance of flow cytometric MRD detection for the first time in Korea. METHODS: We analyzed the results of MRD detection in morphologically complete remission bone marrow aspirates from 89 patients with newly-diagnosed or relapsed acute leukemia, in which leukemic cells had cross-lineage antigen expression. Patients were grouped based on MRD frequencies: > or =1.0%, high MRD; <1.0%, low MRD. RESULTS: Forty-seven ALL patients consisted of 10 with high and 37 with low MRD levels. Patients with high MRD levels showed a tendency of more frequent relapse than those with low MRD levels (40.0% and 13.5%, respectively) (P=0.08). High MRD group showed a tendency of short relapse-free survival (RFS) and overall survival (OS), although the differences were not statistically significant. Forty-two AML patients consisted of 16 with high and 26 with low MRD levels. There were no correlations between the MRD levels and relapse rate, RFS or OS. AML patients with high MRD levels showed significantly higher rate of unfavorable cytogenetic risk categories and lower rate of favorable risk categories (P=0.03). CONCLUSIONS: MRD detection by flow cytometric assay of cross-lineage antigen expression would be useful in predicting treatment outcome in patients with ALL rather than AML. We expect that the establishment of the standardization of methods, time to test or antibody combination would be achieved through further trials in this country.
